My sixteen year old son died by suicide in June of 2007 within hours of his first dose of Strattera given to us in sample form, without the fact sheet the FDA asked Eli Lilly to provide doctors and pharmacists with, in order to pass on to care givers. My son was diagnosed by a neuropsychologist, at the urging of his teachers three years earlier when he was 13, with Executive Function Disorder (a learning disability characterized by a marked disparity between ability and performance). His teachers loved him and referred to him as an absent minded professor (high I.Q. with failing grades). So his struggle with academics was nothing new, when I agreed to try the non-stimulant, SSRI containing medication Strattera as an alternative to Adderall which didn't really help with his academic performance and also made him jittery, in an attempt to help him have academic success in high school. My only concern with the possible side affect of drowsiness at school. I was told by his pediatrician of the FDA black box warning of the possibility of suicidal thoughts or actions, but because I had no indication from him that he was depressed or that he was in any way (impulsive) in danger of hurting himself, I wasn't concerned about it. I gave him his first dose at 1pm, asked him to let me know if it made him drowsy, upset his stomach or made him feel different in any way. Between 1 and 6:45 pm, when I left to go to a movie with my sister, I asked him repeatedly if he noticed any change to which he responded no. At around 8p.m., my husband and younger son left him alone at home to go to make a quick trip to the store to get dessert. Our son died by suicide while they were at the store. When a family friend who happens to be a pharmacist heard the news, her first question was whether or not he was taking any medication. When she heard it was Strattera she was horrified and dismayed that a pediatrician would give a sample of Atomoxetine to the parent of an adolescent. The black box warning says to closely monitor children and adolescents when starting or changing the dosage of this medication. I could go on and on about the articles I've read, programs I've watched and the German public television documentarian who contacted us since losing our son, because of the high rate of Strattera related adolescent suicides in Europe where Strattera has been available longer that in the U.S. In short, the warning should be changed to, "CLOSELY MONITOR AND DO NOT LEAVE CHILDREN OR ADOLESCENTS ALONE WHEN STARTING OR CHANGING THE DOSAGE OF THIS MEDICATION BECAUSE OF THE POSSIBILITY OF AN ADVERSE BIOCHEMICAL AFFECT ON THE BRAIN THAT COULD CAUSE SERIOUS INJURY OR DEATH." My son was a beautiful sweet boy, loved by all who knew him, and what the neuropsychologist who tested him in seventh grade and his teachers agreed, an extremely bright boy with limitless potential. I know there are children and adolescents who benefit from Strattera and medications like it, but please, err on the side of caution, and do not leave them alone when starting or changing the dosage.